Despite five cell cycle inhibitors failing in phase II glioma clinical trials due to conceivably being ABC transporter substrates, two single drugs (fotemustine and valganciclovir) and two combination drugs (eflornithine and celecoxib) exceeded the primary survival outcome alone or combined with AntiBCs in phase I/II clinical trials. Here, ABCG2 is linked to glioma.